Article

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

2021-10-14

Abstract excerpt

<h4>Background</h4> Over 400 variants in the cystic fibrosis (CF) transmembrane conductance regulator ( CFTR ) are CF-causing. CFTR modulators target variants to improve lung function, but marked variability in response exists and current therapies do not address all CF-causing variants highlighting unmet needs. Alternative epithelial ion channel/transporters such as SLC26A9 could compensate for CFTR dysfunction,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8540f82f-c96a-5522-9feb-f6a74984cbcc
DOI: 10.1101/2021.10.07.21264392

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung diseaseDOI 10.1101/2021.10.07.21264392Read

The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?Semantic proximity Read

INTEGRATING GENOMIC AND FUNCTIONAL TESTING TO IMPROVE CFTR MODULATOR RESPONSE PREDICTION IN CHILDREN WITH CYSTIC FIBROSISSemantic proximity Read

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.Semantic proximity Read

Cystic Fibrosis: Modern Diagnostic and Therapeutic Advances from Molecular Pathogenesis to Multidisciplinary Management.Semantic proximity Read

SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.Semantic proximity Read

The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.Semantic proximity Read

Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine.Semantic proximity Read

A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.Semantic proximity Read

Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.Semantic proximity Read

Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies.Semantic proximity Read

The Solute Carrier Family 26 Member 9 Is a Modifier of the Rapidly Progressing Cystic Fibrosis Associated with F508del CFTR MutationsSemantic proximity Read

Pharmacogenetics and Theratyping in Pulmonology: A Practical GuideSemantic proximity Read